…
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that is in Phase 2 clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease, which is in Phase 3 clinical trial; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL8177, an oral peptide formulation for treatment of ulcerative colitis, which entered Phase 2 clinical trials. The company was founded in 1986 and is based in Cranbury, New Jersey.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Palatin Technologies is a small biopharmaceutical company developing receptor-targeted peptide therapeutics and pursuing value through licensing, partnerships and commercialization arrangements. Long-term growth may be driven by clinical progress of its development programs, milestone or royalty receipts from partnered products, and new collaboration deals. Investors may find exposure to niche receptor-focused drug programs and binary upside from successful trials or licensing outcomes.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
| Income before tax | -32.22M | -36.20M | -33.60M | -22.43M | 35.77M |
| Net income | -27.54M | -35.81M | -33.57M | -22.38M | 35.77M |
| Selling general administrative | 15.29M | 16.51M | 17.34M | 9.77M | 9.70M |
| Gross profit | 4.44M | 1.25M | -0.34M | 0.12M | 60.30M |
| Reconciled depreciation | 0.29M | 0.13M | 0.05M | 0.06M | 0.06M |
| Ebit | -32.75M | -36.72M | -33.38M | -23.67M | 35.74M |
| Ebitda | -32.46M | -36.59M | -30.60M | -23.61M | 35.80M |
| Depreciation and amortization | 0.29M | 0.13M | 2.78M | 0.06M | 0.06M |
| Non operating income net other | - | - | - | 1.20M | 0.45M |
| Operating income | -32.46M | -36.59M | -33.38M | -23.61M | 35.74M |
| Other operating expenses | 38.34M | 38.06M | 30.41M | 23.72M | 24.56M |
| Interest expense | 0.02M | 0.03M | 0.02M | 0.02M | 0.42M |
| Tax provision | -4.67M | - | - | 0.00M | 0.00M |
| Interest income | 0.24M | 0.39M | 0.21M | 1.18M | 0.03M |
| Net interest income | -0.02M | -0.03M | -0.02M | -0.02M | -0.42M |
| Income tax expense | -4.67M | -0.39M | -0.03M | -0.04M | -0.45M |
| Total revenue | 4.85M | 1.47M | -0.19M | 0.12M | 60.30M |
| Total operating expenses | 37.92M | 37.84M | 30.26M | 23.72M | 24.56M |
| Cost of revenue | 0.42M | 0.22M | 0.15M | - | 14.86M |
| Total other income expense net | 0.24M | 0.39M | -0.21M | 1.18M | 0.03M |
| Net income from continuing ops | -27.54M | -36.20M | -33.60M | -22.43M | 35.77M |
| Net income applicable to common shares | -27.54M | -36.20M | -33.60M | -22.43M | 35.77M |
| Breakdown | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
| Total assets | 17.94M | 36.07M | 67.30M | 85.05M | 104.74M |
| Other current assets | 1.90M | 0.67M | 1.15M | 0.61M | 0.49M |
| Total liab | 17.81M | 19.80M | 17.65M | 4.88M | 4.19M |
| Total stockholder equity | 0.13M | 16.27M | 49.65M | 80.17M | 100.55M |
| Other current liab | 10.37M | 12.63M | 3.72M | 2.90M | 0.50M |
| Common stock | 0.12M | 0.09M | 2.30M | 2.29M | 2.27M |
| Capital stock | 0.12M | 0.09M | 2.30M | 2.29M | 2.27M |
| Retained earnings | -415.54M | -387.99M | -351.80M | -318.20M | -295.77M |
| Other liab | 2.08M | 2.86M | 6.23M | - | - |
| Other assets | 0.06M | 0.06M | 0.06M | 0.06M | 0.18M |
| Cash | 7.99M | 29.94M | 60.10M | 82.85M | 43.51M |
| Cash and equivalents | 7.99M | 29.94M | 60.10M | 82.85M | 43.51M |
| Total current liabilities | 15.13M | 16.26M | 10.51M | 3.93M | 4.19M |
| Current deferred revenue | - | - | 5.80M | - | 2.85M |
| Net debt | -6.94M | -28.79M | -58.85M | -81.59M | -43.18M |
| Short term debt | 0.46M | 0.47M | 0.35M | 0.31M | 0.33M |
| Short long term debt | - | - | - | - | 0.33M |
| Short long term debt total | 1.05M | 1.15M | 1.25M | 1.27M | 0.33M |
| Other stockholder equity | 397.73M | 404.17M | 399.15M | 396.08M | 394.05M |
| Property plant equipment | 1.56M | 1.42M | 1.33M | 1.41M | 0.14M |
| Total current assets | 16.32M | 34.60M | 65.91M | 83.59M | 104.41M |
| Net tangible assets | 0.13M | 16.27M | 49.65M | 80.17M | 100.55M |
| Short term investments | 2.99M | - | - | - | - |
| Net receivables | 2.92M | 1.78M | 1.58M | 0.00M | 60.27M |
| Long term debt | - | - | - | - | 0.00M |
| Inventory | 0.53M | 0.94M | 1.16M | - | 0.15M |
| Accounts payable | 4.30M | 3.16M | 0.64M | 0.72M | 0.50M |
| Accumulated other comprehensive income | -0.12M | - | - | -2.45M | -2.39M |
| Common stock total equity | - | - | 2.30M | 2.29M | 2.27M |
| Preferred stock total equity | - | - | - | 0.00M | 0.00M |
| Retained earnings total equity | - | - | - | -318.20M | -295.77M |
| Non currrent assets other | 0.06M | 0.06M | 0.06M | 0.06M | 0.18M |
| Non current assets total | 1.62M | 1.47M | 1.39M | 1.46M | 0.32M |
| Capital lease obligations | 1.05M | 1.15M | 1.25M | 1.27M | - |
| Long term debt total | 0.05M | 0.15M | 0.00M | 0.00M | 0.00M |
| Breakdown | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
| Investments | -3.43M | -0.26M | -0.01M | -0.06M | -0.04M |
| Change to liabilities | 1.11M | 2.57M | -0.08M | 0.26M | -0.97M |
| Total cashflows from investing activities | -3.43M | -0.26M | -0.01M | -0.06M | -0.04M |
| Net borrowings | -0.10M | -0.06M | -0.06M | -0.83M | -6.50M |
| Total cash from financing activities | 9.90M | 0.02M | -0.09M | -1.92M | 27.33M |
| Change to operating activities | -2.74M | 0.85M | -9.26M | -0.23M | 0.84M |
| Net income | -27.54M | -36.20M | -33.60M | -22.43M | 35.77M |
| Change in cash | -21.95M | -30.17M | -22.75M | 39.34M | 5.51M |
| Begin period cash flow | 29.94M | 60.10M | 82.85M | 43.51M | 38.00M |
| End period cash flow | 7.99M | 29.94M | 60.10M | 82.85M | 43.51M |
| Total cash from operating activities | -28.42M | -29.92M | -22.65M | 41.33M | -21.78M |
| Issuance of capital stock | 10.14M | - | 0.00M | 1.58M | 33.14M |
| Depreciation | 0.29M | 0.13M | 0.05M | 0.06M | 0.06M |
| Other cashflows from investing activities | -2.99M | - | - | 0.00M | 0.00M |
| Change to inventory | 0.42M | 0.22M | -0.99M | -0.52M | 0.78M |
| Change to account receivables | -1.14M | -0.20M | -1.58M | 60.27M | -60.27M |
| Sale purchase of stock | 10.14M | 0.30M | 0.00M | 1.58M | 33.94M |
| Other cashflows from financing activities | -0.15M | 0.06M | -0.09M | -2.67M | 0.69M |
| Change to netincome | 1.18M | 2.71M | 22.80M | 3.14M | 3.48M |
| Capital expenditures | 0.43M | 0.26M | 0.01M | 0.06M | 0.04M |
| Change receivables | - | - | - | 60.27M | -60.27M |
| Cash flows other operating | - | - | - | 0.02M | 0.09M |
| Cash and cash equivalents changes | - | - | - | 39.34M | 5.51M |
| Change in working capital | 0.39M | 3.44M | -11.90M | 60.25M | -61.15M |
| Stock based compensation | 1.41M | 2.51M | 3.17M | 3.14M | 3.48M |
| Other non cash items | -2.58M | 0.20M | 19.42M | 0.30M | 0.05M |
| Free cash flow | -28.85M | -30.18M | -22.65M | 41.26M | -21.82M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| PTN Palatin Technologies, Inc. Common Stock |
-0.77 12.49% |
5.36 | - | - | 5.61 | 4.25 | 4.82 | -0.99 |
| NVO Novo Nordisk A/S |
-0.99 2.39% |
40.60 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-3.90 0.73% |
533.89 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
5.36 0.56% |
957.76 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
965.00 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that is in Phase 2 clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease, which is in Phase 3 clinical trial; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL8177, an oral peptide formulation for treatment of ulcerative colitis, which entered Phase 2 clinical trials. The company was founded in 1986 and is based in Cranbury, New Jersey.
Cedar Brook Corporate Center, Cranbury, NJ, United States, 08512
609 495 2200
34
| Name | Title | Year Born |
|---|---|---|
| Dr. Carl Spana Ph.D. | Co-Founder, Pres, CEO & Director | 1962 |
| Mr. Stephen T. Wills CPA, CPA, MST | CFO, COO, Exec. VP, Treasurer & Sec. | 1957 |
| Burns McClellan | VP of Investor Relations | NA |
| Mr. Stephen A. Slusher Esq. | Chief Legal Officer | NA |
| Dr. Michael B. Raizman M.D. | Chief Medical Officer | NA |
| Mr. James E. Hattersley | Sr. VP of Bus. Devel. | 1960 |
| Mr. John Dodd Ph.D. | Sr. VP of Preclinical Devel. | NA |
| Mr. Robert Jordan | Sr. VP of Program Operations | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.